This was a relatively busy week with new draft guidances, new orphan drug designations, two supplemental approvals, and the lifting of a clinical hold.  Here are the top regulatory stories for this week: The Food and Drug Administration has approved the first artificial intelligence software that can decide, without a clinician’s involvement, whether a patient[…]